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A B S T R A C T
Background: Severe cases of primary HIV infection have been described in patients presenting with
neurological involvement, AIDS defining events or other life-threatening events. These severe forms have
not been fully studied.
Objectives: To determine the prevalence and characteristics of severe PHI in a hospital-based cohort of
primary HIV infection, and the response to the early initiation of antiretroviral therapy (ART) at
12 months.
Methods: Every patient with PHI attending Hospital Clínic of Barcelona (1997–2015) was evaluated.
Severe PHI was defined using clinical, analytical and immunological criteria. Chi-squared test was used
for categorical variables and Student’s t-test for quantitative variables.
Results: 33% of 224 PHI patients (95% CI: 26.84%–39.16%) had a severe PHI. These patients had more
symptoms, abnormal analytical parameters and hospital admissions. The severe PHI group had a
significantly higher viral load although no differences were observed at 12 months in terms of viral
suppression or CD4 count recovery. None died during PHI.
Conclusions: Up to one third of patients in our cohort presented with a severe PHI, which was associated
with higher hospitalization rates and higher plasma HIV RNA viral load. However, severe forms were not
associated to a worse clinical, immunological or virological outcome at 12 months.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Primary HIV-1 infection (PHI) usually presents with non-
specific symptoms in a variable proportion of patients, ranging
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).based or community based cohorts) (Sued et al., 2006; Braun
et al., 2015). Typical HIV symptoms are mild and resemble a
mononucleosis-like syndrome, with fever, asthenia, pharyngitis,
rash, and lymphadenopathies being the most frequent. However,
some patients present more severe forms of infection such as
opportunistic infections (Braun et al., 2015), neurological
involvement (Ambrosioni et al., 2017) and other serious
conditions. Although many individual cases have been reported,
a systematic study and definition of the incidence and character-
istics of severe PHI is lacking. Some features during PHI have been
associated with disease progression (AIDS/death). These events
were: a low CD4 count at diagnosis, some pre-defined severe
symptoms and central nervous system involvement (Lodi et al.,
2013). In 2014 an Acute HIV Severity Index based on these criteria
was proposed by Braun et al (Braun et al., 2014). In recent years
early treatment initiation in every HIV-diagnosed patient hasiety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Flow chart representing the inclusion of patients in the severe and non-
severe groups.
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recommendation in all international guidelines (INSIGHT START
Study Group et al., 2015; European AIDS Clinical Society, 2017;
Günthard et al., 2016).
The aim of this study was to describe the prevalence and the
characteristics of patients with severe PHI in a large hospital-based
single center. We also aim to evaluate the differences in
immunological and virological outcome at 12 months between
both severe and non-severe groups.
Methods
The ‘Hospital Clinic Acute/Recent HIV Infection Cohort’
comprises 346 consecutive patients between April 1997 and
December 2015. Hospital Clinic is a public, tertiary teaching
hospital which serves 560,000 people in the metropolitan area of
Barcelona. The catchment area and the patient recruitment have
remained unchanged during the study period. Approximately
5,000 HIV-positive patients are on active follow up and more
than 90% are on antiretroviral therapy (ART). For the purpose of
this study, only the patients with confirmed PHI with less than
90 days were selected (N = 224, Fiebig I-V) defined by one of the
following at diagnosis: a negative ELISA with a detectable viral
load or a positive p24 antigen or a positive ELISA with a negative,
indeterminate or incomplete (lacking p31 band) Western blot
(Fiebig et al., 2003). Patients were actively questioned and
examined for clinical signs and symptoms of seroconversion at
the first clinical visit. Clinical follow up and blood samples,
including viral subtype and tropism, were obtained at diagnosis
and at the time of ART initiation, and every six months thereafter
(Sued et al., 2006; Nicolás et al., 2018).
Study definitions
PHI was defined as a confirmed infection of less than 90 days
according to the different Fiebig stages, defined by one of the
following: a negative ELISA with a detectable viral load or a
positive p24 antigen or a positive ELISA with a negative, an
indeterminate or incomplete Western blot (Fiebig stages I to V)
(Fiebig et al., 2003). Severe PHI was defined as those patients
presenting at least one clinical, analytical or immunological
severity criterion based on previously published works (Lodi
et al., 2013; Braun et al., 2014). Clinical severity was defined as
presenting a B or C event of the CDC classification (Schneider
et al., 2008), neurological manifestations or non-hepatotropic
virus related hepatitis (determined as presenting analytical levels
of either aspartate aminotransferase/ASAT or alanine aminotrans-
ferase/ALAT at diagnosis 10 times higher than the upper normal
values range with absence of active hepatitis A, hepatitis B virus
or hepatitis C virus infection markers). Analytical severity was
defined as severe thrombocytopenia (platelets below 100  109/L,
according to the WHO classification), and immunological severity
was established with CD4 counts below 350 cells/mm3 at the
moment of the diagnosis (Figure 1). Comorbidities were
determined according to the Charlson Comorbidity Index
(Charlson et al., 1987).
Statistical analysis
Chi-squared test was used for dichotomous and nominal
variables and Student’s t-test for continuous quantitative variables.
Finally, a comparison of the evolution of immunologic and
virologic parameters during one year in patients who started
early ART was made between severe and non-severe groups. IBM
SPSS program (version 19.0) was used to carry out the statistical
analyses.Results
Main epidemiological characteristics of PHI cohort
A total of 224 patients presented with a PHI of less than 90 days
between 1997 and 2015 and, of them, 74 (33%) (95% CI: 26.84-
39.16) presented with a severe form of PHI. Baseline characteristics
are shown in Table 1. The cohort was composed of 210 (93.8%)
males and 14 (6.3%) females, with a median age at diagnosis of 35
years (interquartile range 29-39). At diagnosis, 38 (17.0%) patients
were identified as Fiebig II stage, 28 (12.5%) as Fiebig III, 58 (25.9%)
as Fiebig IV and 100 (44.6%) as Fiebig V. None was diagnosed at
Fiebig I stage. The majority of patients, 141 (63.2%), were Spanish-
born, whereas 82 (36.8%) were migrant. The main risk factor for
HIV infection acquisition was men-who-have-sex-with-men
(MSM), present in 190 (85.6%) patients, followed by heterosexual
relations, 21 (9.5%) patients, and intravenous drug users (IVDU), 11
(5.0%) patients. Thirty-six (16.1%) patients presented with con-
comitant STD (syphilis or/and Hepatitis virus C) and 30 (13.4%)
presented other comorbidity (by Charlson index).
Characteristics of severe PHI
Of the 74 (33%) patients presenting a severe PHI, 30 (13.4%)
patients qualified as severe PHI according to clinical criteria, three
(1.3%) patients presented bacterial pneumonia, 14 (6.3%) oral
candidiasis, seven (3.1%) pharyngeal candidiasis, two (0.9%)
esophageal herpes, 11 (4.9%) meningoencephalitis, one (0.4%)
prolonged fever (over 1 month) and one (0.4%) prolonged diarrhea
(over 1 month). With respect to immunological severity criteria, a
Table 1
Epidemiologic and clinical characteristics of patients with PHI and differences between severe and non-severe patients.
Condition Overall Severe Non-severe p
N = 224 N = 74 N = 150
Fiebig at diagnosisa 0.279
II (positive p24) 38 (17.0) 17 (23.0) 21 (14.0) 0.767
III (positive ELISA) 28 (12.5) 10 (13.5) 18 (12.0) 0.747
IV (indeterminate Western blot) 58 (25.9) 15 (20.3) 43 (28.7) 0.177
V (incomplete Western blot) 100 (44.6) 32 (43.2) 68 (45.3) 0.767
Gender
Male 210 (93.8) 71 (95.9) 139 (92.7) 0.340
Female 14 (6.3) 3 (4.1) 11 (7.3)
Age at diagnosisb 35  8 36  9 34  8 0.142
Origin
Spain 141 (63.2) 43 (58.1) 98 (65.8) 0.264
Migrant 82 (36.8) 31 (41.9) 51 (34.2)
HIV risk factor
HTX 21 (9.5) 6 (8.2) 15 (10.1) 0.616
MSM 190 (85.6) 62 (84.9) 128 (85.9)
IDU 11 (5.0) 5 (6.8) 6 (4.0)
Symptomatic PHI 190 (84.8) 73 (98.6) 117 (78.0) <0.001
Fever 180 (80.4) 71 (95.9) 109 (72.7) <0.001
Fever 7 days 110 (53.9) 55 (77.5) 55 (41.4) <0.001
Asthenia 139 (62.1) 58 (78.4) 81 (54.0) <0.001
Rash 80 (35.7) 36 (48.6) 44 (29.3) 0.005
Headache 76 (33.9) 34 (45.9) 42 (28.0) 0.008
Myalgia 101 (45.1) 36 (48.6) 65 (43.3) 0.452
Night sweating 49 (21.9) 18 (24.3) 31 (20.7) 0.533
Pharyngitis 83 (37.1) 34 (45.9) 49 (32.7) 0.053
Oral/genital ulcers 38 (17.0) 16 (21.6) 22 (14.7) 0.192
Splenomegaly 4 (1.8) 3 (4.1) 1 (0.7) 0.072
Hepatomegaly 10 (4.5) 5 (6.8) 5 (3.3) 0.243
Gastrointestinal symptoms 67 (29.9) 32 (43.2) 35 (23.3) 0.002
Lymphadenopathies 98 (43.8) 38 (51.4) 60 (40.0) 0.107
Hospitalization required 57 (25.4) 35 (47.3) 22 (14.7) <0.001
Concomitant STD 36 (16.1) 6 (8.1) 30 (20.0) 0.023
Comorbidities 30 (13.4) 14 (18.9) 16 (10.7) 0.088
ART scheme
2NRTI + NNRTI 64 (30.0) 20 (28.6) 44 (30.8) 0.862
2NRTI + InSTI 56 (26.3) 20 (28.6) 36 (25.2)
2NRTI + PI 93 (43.7) 30 (42.9) 63 (44.1)
ART beginning <1 month 71 (31.7) 31 (41.9) 40 (26.7) 0.021
ART beginning <3 months 124 (55.4) 41 (55.4) 83 (55.3) 0.992
ART beginning <6 months 147 (65.6) 52 (70.3) 95 (63.3) 0.304
Abbreviations: HTX = heterosexual, MSM = Men Sex Men, IDU = Intravenous Drug Users, ART = Antiretroviral Treatment, NRTI = Nucleoside Reverse Transcriptase Inhibitor,
NNRTI = Non Nucleoside Reverse Transcriptase Inhibitor, InSTI = Integrase Strand Transfer Inhibitor, PI = Protease Inhibitor.
a N (%).
b Mean  standard deviation.
Table 2
Clinical, biochemical and immunological characteristics of patients with severe PHI
(N = 74).
Severe PHI condition 74 (33)a
Clinical severityb 30 (13.4)
Hepatitisc
,d 6 (2.9)
Bacterial pneumonia 3 (1.3)
Oral candidiasis 14 (6.3)
Esophageal candidiasis 7 (3.1)
Esophageal herpese 2 (0.9)
Fever > 1 month 1 (0.4)
Diarrhea >1 month 1 (0.4)
Meningoencephalitisf 11 (4.9)
CD4 at diagnosis below 350 cells/mm3 56 (25.0)
Platelets at diagnosis below 100c 5 (2.4)
Abbreviations: PHI = Primary HIV Infection.
a N (%).
b Any of the below criteria.
c Platelets n = 206, transaminases n = 208.
d Active HBV/HCV infection excluded.
e In 2 cases, together with esophageal candidiasis.
f In 2 cases, together with oral candidiasis.
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patients, severe thrombocytopenia was found in five (2.4%)
patients and non-viral hepatitis in six (2.9%) patients (Table 2).
Comparison of epidemiological, clinical, immunological and
virological features between severe PHI and non-severe PHI
The differences in baseline characteristics between the severe
and non-severe groups are represented in Tables 1 and 3. The mean
year of infection was 2009 for the severe group and 2008 for the
non-severe (p = 0.148). Regarding virological features, significant
differences were found between both groups in baseline viral load,
presenting a mean of 5.71 log10 copies/mL in the severity group
and 4.81 log10 copies/mL in the non-severe group (p < 0.001). No
significant differences were observed in viral tropism or in viral
subtype between groups. No significant differences were found in
the proportion of primary transmitted drug resistance mutations
between groups (9.34% in the non-severe vs. 4.05% in the severe,
p = 0.160) (Tables 1 and 3).
Table 3
Main coagulation, biochemical, immunological and virological features of patients with PHI and differences between severe and non-severe patients (N = 224).
Parameter N Overall Severe Non-severe p
N = 224 N = 74 N = 150
Coagulation variables
Plateletsa (109/L) 206 241.25  87.86 217.90  98.94 254.06  78.62 0.004
Biochemical variables
Creatine Kinase (IU/L) 176 145.69  209.02 141.08  184.96 148.13  221.46 0.832
ASAT (mU/mL) 208 56.00  93.87 87.42  132.59 39.01  57.76 <0.001
ALAT (mU/mL) 208 78.07  127.18 120.85  161.66 54.94  97.00 <0.001
GGT (IU/L) 200 58.89  89.30 91.89  125.54 40.34  52.16 <0.001
AP (IU/L) 199 171.28  172.52 203.90  271.02 152.79  66.53 0.044
Bilirubin (mg/100 mL) 205 0.60  0.29 0.57  0.24 0.61  0.32 0.301
LDH (IU/mL) 190 479.62  208.21 564.93  294.46 432.07  115.48 <0.001
Immunological variables
CD4 (cells/mm3) 224 523.21  280.70 322.69  142.16 622.13  285.63 <0.001
CD8 (cells/mm3) 222 1.134.13  822.96 1.093.37  1073.63 1.154.09  670.32 0.607
CD4/CD8 222 0.65  0.49 0.53  0.52 0.71  0.46 0.009
Virological variables
Viral load (log10 copies/mL) 218 5.11  1.18 5.71  0.93 4.81  1.18 <0.001
Viral subtypeb 139 0.799
B subtype 114 (82) 38 (80.9) 76 (82.6)
Non-B subtype 25 (18) 9 (19.1) 16 (17.4)
TDRb
Overall 17 (7.59) 3 (4.05) 14 (9.34) 0.160
PI1 3 (1.34) 0 3 (2.0) 0.220
NRTI2 3 (1.34) 0 3 (2.0) 0.220
NNRTI3 11 (4.91) 3 (4.05) 8 (5.34) 0.676
Tropismb 90 0.172
R5 72 (80.0) 26 (83.9) 46 (78.0)
X4 12 (13.3) 5 (16.1) 7 (11.9)
Dual 6 (6.7) 0 (0.0) 6 (10.2)
Abbreviations: ASAT (aspartate aminotransferase), ALAT (alanine aminotransferase), GGT (gamma-glutamyl transpeptidase), AP (alkaline phosphatase), LDH (lactate
dehydrogenase).
a Mean  standard deviation.
b Frequency (%).
1 Patients with at least one TDR for PI, including: M46I/L, V82T/F/A, L90M, Q58E, I84V, I54L.
2 Patients with at least one TDR for NRTI, including: T215F/Y/X, M41L, L210W, K219E/Q, K219R, K70R, D67N, K219E/Q, K219N/R, M184V, T69N.
3 Patients with at least one TDR for NNRTI, including: Y181C, V108I, K103N, K101E, E138A.
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observed in the proportion of patients presenting fever (95.9%
in severe PHI vs 72.7% in non-severe PHI; p < 0.001), patients with
fever duration longer than one week (77.5% vs 41.4%; p < 0.001),
asthenia (78.4% vs 54%; p < 0.001), skin rash (48.6% vs 29.3%;
p = 0.005), headache (45.9% vs 28%; p = 0.008), mononucleosis-like
syndrome (20.3% vs 9.3%; p = 0.022) and gastrointestinal symp-
toms (43.2% vs 23.3%; p = 0.002). However, no significant differ-
ences were observed among the proportions of patients presenting
myalgia, nocturnal sweating, pharyngitis, ulcers, splenomegaly,
hepatomegaly, and lymphadenopathies.
Finally, in the epidemiological data, patients with severe PHI
presented significantly less concomitant STDs than non-severe
patients (8.1% vs 20%; p = 0.023). Also, the proportion of patients
requiring hospitalization during the PHI was significantly higher
in the severe group (47.3% vs 14.7%, p < 0.001). No significant
differences were found in Fiebig stage at diagnosis, gender, age at
diagnosis, origin, HIV risk factor and Charlson index (Table 1).
Virological and immunological response to early ART beginning
For the analysis of the virological and immunological outcome,
we included every patient starting ART during the first six months
of infection (n = 147) and follow up for one year from starting
ART. A progressive increase in CD4 cell counts was observed at
three, six and 12 months in both severe and non-severe PHI
groups: 544.38 cells/mm3, 628.8 cells/mm3 and 769.85 cells/mm3
respectively in the severe group (329.67 cells/mm3 at baseline) and
661.48 cells/mm3, 784.06 cells/mm3, 859.19 cells/mm3 in the non-
severe group (633.16 cells/mm3 at baseline). These differences
were statistically significant at six months (p = 0.003), beingcomparable at 12 months (p = 0.124) (Figure 2a). No significant
variations were detected in the CD8 cell count. CD4/CD8 ratio
presented a significant trend, increasing progressively at three, six
and 12 months: 0.59, 0.75 and 0.93 respectively (0.51 at baseline)
in the severe group and 0.81, 0.99,1.14 (0.69 at baseline) in the non-
severe group (p = 0.014 at month 12). Finally, viral load suppression
is shown in Figure 2b. The proportion of patients with undetect-
able viral load increases progressively from baseline to three, six
and 12 months; being 2.9%, 64% and 93.8% respectively in the
severe group and 11.5%, 73.9% and 95.2% in the non-severe group,
with no significant differences at any time point. We also analyzed
the immunological and virological responses to ART in three time
periods (1997-2003, 2003-2008, 2009-2015) in order to identify
differences in the outcome due to management recommendations
for PHI or different ART schemes, without finding statistically
significant differences (see Supplementary material).
As shown in Table 1, no significant differences were found in the
proportion of patients beginning ART in the first three to six
months after HIV diagnosis. However, the proportion of patients
starting ART during the first month was significantly higher in the
severe group (41.9% vs 26.7%, p = 0.021). No differences were found
in either group regarding the ART treatment scheme.
Clinical outcome
No patient died during the PHI phase. Only three (1.7%) patients
out of 224 died during the follow up, two from the non-severe
group (1 drug overdose after 6.2 years of follow up and 1
pulmonary Kaposi sarcoma due to a limited adherence to ART after
2.1 years of follow up) and one from the severe group (unknown
cause of death occurring after 7.9 years of follow up).
Figure 2. (a) Evolution of CD4 cells at 12 months in patients starting antiretroviral treatment within the first 180 days of PHI diagnosis (N = 147). (b) Evolution of viral load
suppression at 12 months in patients starting antiretroviral treatment within the first 180 days of PHI diagnosis.
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Of the 224 patients presenting with PHI (Fiebig stages I-V) at the
Hospital Clinic of Barcelona, 33% presented a severe infection
according to our study definition, with clinical severity present in
13%, immunological severity (CD4 count <350 cells/mm3) in 25%and neurological events in 4.9%. These results are consistent with
previous reports from the CASCADE cohort (Lodi et al., 2013),
although in this cohort only 14.9% of patients presented clinical
severity. The criteria for severity were similar in both cohorts:
28.3% presented CD4 counts below 350 cells/mm3 and neurologic
involvement was present in 4.5%. The cohorts differ in several
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patients were MSM as an HIV risk factor, whereas in the Lodi S et al
study it is 71%. There are also differences in gender (6.3% vs 15%
female) and median age at diagnosis (35 vs 29 years). However,
both cohorts were comparable in terms of median CD4 counts at
diagnosis.
Only a few published studies have compared clinical, immuno-
logical, analytical and virological characteristics between severe
and non-severe PHI. However the correlation between viral load at
PHI, viral load set point and symptoms is well established in
English-language literature (Kelley et al., 2007; Robb et al., 2016).
According to our data, severe PHI was associated with a
significantly higher viral load at diagnosis, resulting in a one
logarithmic difference (5.71 log10 vs 4.81 log10 copies/mL).
These results are consistent with those described by Braun et al,
who established a correlation between severity (which they
had previously defined on the basis of neurological symptoms,
hospitalization, age, elevated fever, elevated liver enzymes and
thrombocytopenia, and viral load and CD4 cell count at baseline)
and higher viral load and lower CD4 cell counts (Braun et al., 2014).
It is well known that X4 viral tropism is associated with lower
baseline CD4 cell count, higher viral load and major risk of disease
progression (Daar et al., 2007), but no relationship was discovered
between viral tropism and PHI severity in our study, although the
small proportion of X4 patients in our cohort limits the statistical
power of this association.
In the epidemiological data, no significant differences were
found between groups in Fiebig stage, gender, age at diagnosis,
associated comorbidities or risk factor for HIV infection, which
suggests that the severity of the PHI does not depend on the route
of transmission. Surprisingly, significant differences were ob-
served when comparing groups for the presence of concomitant
STDs at diagnosis, where non-severe forms appeared to be more
associated to a higher prevalence of STDs (8.1% in severe PHI vs
20.0% in non-severe PHI). This association may be explained by a
more frequent and earlier consultation in hospitals of patients with
STDs, causing a more frequent and earlier HIV diagnosis rate, even
in asymptomatic patients.
The CD4 T-cell count differences between groups are not
comparable because low CD4 count at diagnosis was one of the
defining criteria for severity. However, it is interesting to highlight
that no significant differences were seen in CD8 cell counts, which
in both groups greatly increased, showing that, when faced with a
PHI, high immune system activation is present independent of the
presence or otherwise of a severe form.
This study compared the response to early ART (i.e., adminis-
trated in a period of time below 180 days from the diagnosis)
from severe and non-severe PHI and showed that, despite the one
log10 copies/mL difference in viral load between both groups at
baseline, there is a trend to suppression until being undetectable
in proportions over 90% in both groups in the period of a year.
Furthermore, the proportion of viral suppression after ART
initiation did not show any significant difference at any time
point. Remarkably, early ART initiation was also associated with a
progressive increase in CD4 cell counts in both groups (increasing
in 471.79 cells/mm3 in the severe group and 239.85 cells/mm3 in
the non-severe group) being comparable at 12 months from the
diagnosis. However, patients with non-severe PHI presented a
significantly higher CD4/CD8 ratio at 12 months (0.93 vs 1.14
p = 0.014), consistent with the results of Hoenigl et al, who found
an association between symptomatic acute HIV infection and a
lower CD4/CD8 ratio (Hoenigl et al., 2016). The association
between lower CD4/CD8 ratio and non-AIDS mortality has been
well described (Serrano-Villar et al., 2014; Mussini et al., 2015),
justifying further long-term studies to evaluate the impact of
severe PHI in non-AIDS mortality.When comparing the severity of PHI and the time to starting
ART, no differences were found in the proportion of patients
starting ART within the first two, three and six months; however,
more patients with severe PHI started ART in the first month than
did patients with non-severe PHI. This fact confirms that patients
presenting severity criteria tend to begin ART more quickly. It is
worth noting that in contrast to other countries (Mehraj et al.,
2018), the Spanish health system is free for all people living in
Spain, so there is no economic bias expected in time to ART
initiation in this context. Finally, although a low mortality rate is
expected for this condition, it is important to highlight that,
although the sample is very small, severity of PHI does not seem to
imply a worse outcome in terms of survival rate. There were no
deceases during the initial phase of HIV infection (first 12 months).
Conclusions
Up to 33% of patients from our PHI cohort presented a severe
PHI. Viral load was significantly higher in severe forms, which
were also more symptomatic as expected by definition, required
more hospital admissions, and presented a higher proportion of
abnormal analytical parameters, such as liver function tests.
However, when ART is started early, the immunological or
virological outcomes at 12 months were comparable between
patients with and without severe PHI, although non-severe
patients have a significantly higher CD4/CD8 ratio.
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